VERU INC. Business Acquisition, Pro Forma Net Income (Loss)
VERU INC. (VERU) reported Business Acquisition, Pro Forma Net Income (Loss) of -$8.78 million for the 12-month period ending 2017-09-30, per its 10-K filed 2018-01-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-01-02
- VERU INC. business acquisition, pro forma net income (loss) for fiscal 2017 was -$8.78M.
- VERU INC. business acquisition, pro forma net income (loss) for fiscal 2016 was -$2.36M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2017-09-30 | -$8.78M 10-K · filed 2018-01-02 |
| 2016-09-30 | -$2.36M 10-K · filed 2018-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |